Stock ZYUS ZYUS LIFE SCIENCES CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials ZYUS Life Sciences Corporation

Equities

ZYUS

CA9899601095

Biotechnology & Medical Research

Market Closed - Toronto S.E.
Other stock markets
 03:11:34 2024-04-26 pm EDT 		5-day change 1st Jan Change
1.05 CAD +3.96% Intraday chart for ZYUS Life Sciences Corporation +5.00% +16.67%
Apr. 23 ZYUS Life Sciences Receives US Patent for Pain Management Drug Candidate MT
Mar. 05 Calian Group and MDA Brief: Calian Says "Strengthens Nuclear Capability" with Acquisition of MDA Ltd. Nuclear Assets MT

Valuation

Fiscal Period: December 2023 2024 2025
Capitalization 1 74.39 74.39 -
Enterprise Value (EV) 1 74.39 74.39 74.39
P/E ratio - - -
Yield - - -
Capitalization / Revenue 195 x 155 x -
EV / Revenue 195 x 155 x -
EV / EBITDA -6.41 x -4.89 x -3.03 x
EV / FCF 10.8 x -93 x -
FCF Yield 9.28% -1.08% -
Price to Book - - -
Nbr of stocks (in thousands) 70,847 70,847 -
Reference price 2 1.050 1.050 1.050
Announcement Date - - -
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2023 2024 2025
Net sales 1 0.3815 0.479 -
EBITDA 1 -11.6 -15.2 -24.51
EBIT 1 -13 -17.2 -
Operating Margin -3,407.6% -3,590.81% -
Earnings before Tax (EBT) - - -
Net income - - -
Net margin - - -
EPS - - -
Free Cash Flow 1 6.9 -0.8 -
FCF margin 1,808.65% -167.01% -
FCF Conversion (EBITDA) - - -
FCF Conversion (Net income) - - -
Dividend per Share - - -
Announcement Date - - -
1CAD in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - 0.077 0.099 0.1045 0.1055 0.1065 0.108 0.109
EBITDA 1 - -2.38 -3.173 -4.1 -3.7 -3.7 -3.8 -4
EBIT 1 - -2.982 -3.934 -4.1 -4.3 -4.3 -4.2 -4.3
Operating Margin - -3,872.73% -3,973.74% -3,923.44% -4,075.83% -4,037.56% -3,888.89% -3,944.95%
Earnings before Tax (EBT) - -12 -4.214 - - - - -
Net income -4.681 -11.97 -4.193 - - - - -
Net margin - -15,550.65% -4,235.35% - - - - -
EPS -0.0900 -0.2800 -0.0600 - - - - -
Dividend per Share - - - - - - - -
Announcement Date 6/29/23 8/29/23 11/29/23 - - - - -
1CAD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2023 2024 2025
Net Debt - - -
Net Cash position - - -
Leverage (Debt/EBITDA) - - -
Free Cash Flow 1 6.9 -0.8 -
ROE (net income / shareholders' equity) - - -
ROA (Net income/ Total Assets) - - -
Assets - - -
Book Value Per Share - - -
Cash Flow per Share - - -
Capex 1 0.1 0.05 -
Capex / Sales 26.21% 10.44% -
Announcement Date - - -
1CAD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.05 CAD
Average target price
2.75 CAD
Spread / Average Target
+161.90%
Consensus

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ZYUS LIFE SCIENCES CORPORATION Stock ZYUS Life Sciences Corporation
+16.67% 54.34M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ZYUS Stock
  4. Financials ZYUS Life Sciences Corporation